The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 Å (Angstroms) or less.

The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 Å (Angstroms) or less.

The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.

The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.

Provided herein are polypeptides comprising a therapeutic targeted for delivery to an organ or tissue, and uses thereof.

Provided herein are polypeptides comprising a therapeutic targeted for delivery to an organ or tissue, and uses thereof.

Disclosed is a technique for identifying a mutation of a particular gene as a new case of a FOP-like phenotype, in addition to the existing ACVR1-R206H mutation known as a cause of FOP and utilizing the identified mutation in the bone disease treatment through osteogenic differentiation. There is provided a bone morphogenetic protein type 2 receptor (BMPR2)-E376K mutant in which the 376th amino acid glutamic acid (E) is mutated into lysine (K) in the BMPR2 gene encoding BMPR2.

Disclosed is a technique for identifying a mutation of a particular gene as a new case of a FOP-like phenotype, in addition to the existing ACVR1-R206H mutation known as a cause of FOP and utilizing the identified mutation in the bone disease treatment through osteogenic differentiation. There is provided a bone morphogenetic protein type 2 receptor (BMPR2)-E376K mutant in which the 376th amino acid glutamic acid (E) is mutated into lysine (K) in the BMPR2 gene encoding BMPR2.